Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Politics for Pros- moderated -- Ignore unavailable to you. Want to Upgrade?

To: golfer72 who wrote (773672)	12/12/2022 7:58:02 AM
From: skinowski	2 Recommendations Recommended By Maurice Winn Winfastorlose Read Replies (1) \| Respond to of 793671

I think it’s crazy. Here’s a study - from the NEJM, no less - of the efficiency and safety of CoViD vaccines in young children. Their main focus, it seems, was to show that production of antibodies in young children after vaccination is “not inferior” to other age categories. There were some cases of lab diagnosed CoViD cases during the study period. Was the course of the infections milder? Didn’t see this mentioned. So, the real clinical impact remains unknown. nejm.org